Clover Health (NASDAQ:CLOV) has spent years as a speculative bet on a technology-led Medicare Advantage model. The Q1 2026 report, released May 6, 2026, offered the first quarter that lets bulls make a numbers-based case rather than a narrative one.
The Bull Case: A Profitability Inflection
The Nashville-based insurer swung to GAAP net income of $27.33 million, compared with a $1.27 million loss a year earlier, on revenue of $749.19 million, up 62.05% year over year and topping the $714.89 million estimate by 4.80%. Operating cash flow reached $107.89 million, a 762.22% jump, and adjusted EBITDA of $40 million rose 56% year over year.
Membership scale is the engine. Average Medicare Advantage membership grew 51.6% to 154,607, while adjusted SG&A improved 210 basis points to 15.9% of revenue. CEO Andrew Toy told investors: “Entering 2026, our first quarter results demonstrate how market-leading growth, GAAP net income profitability and full risk can scale together in Medicare Advantage.” He added that “over 1/3 of our members received Clover Assistant-powered care,” with Counterpart Health extending the platform to external payors and providers.
Management reaffirmed FY2026 guidance for revenue of $2.81 billion to $2.92 billion, adjusted EBITDA of $50 million to $70 million, and GAAP net income of $0 million to $20 million, which would mark the company’s first full fiscal year of GAAP profitability.
The Bear Case: Cost Trends and Regulatory Overhang
The Insurance Benefit Expense Ratio rose 40 basis points to 86.5%, with net medical claims growing 65.8% versus premium growth of 62.9%. Unpaid claims climbed to $260.4 million from $153.3 million at year-end 2025. The reported EPS of $0.05 missed the $0.07 estimate by 28.57%.
Valuation leaves little cushion. Trailing metrics show a forward P/E of 82, price-to-book of 6.5, and a beta of 2.42. Volatility is extreme: shares are up 77.5% year to date to $4.17, but down 20.4% over the past month. The net insider trading direction is selling, and Toy himself cautioned that outpatient utilization “continues to be elevated.” CMS rate policy, Star Ratings, and risk-model changes remain persistent overhangs.
Sentiment and the Verdict
Wall Street coverage is thin. The mean price target is $4.58, and the composite prediction sentiment score is a neutral 49.34.
Clover is clearly turning a corner operationally: a real GAAP profit, expanding membership, and Clover Assistant reaching a meaningful share of members. Yet with medical cost trends creeping higher, reserves building, and the stock priced at about 82 times forward earnings, the corner has already been partly priced in. The turnaround is credible; the margin of safety is slim. Investors should monitor Q2 2026 results and any updated guidance for confirmation.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks